Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 90

Sort by

Sort Order Select

Journal Articles

Methylation Biology of a Blood-Based MDS Risk Stratification Test

Alvin Shi, Abdullah Mahmood Ali, Gordon Cann, Rita Shaknovich, Oliver Venn, Azra Raza, Qinwen Liu

Blood (2023) 142 (Supplement 1): 4599.

https://doi.org/10.1182/blood-2023-180256

Published: 2023

Journal Articles

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Brian Chernak, Marta Galan-Diez, Abdullah Mahmood Ali, Alvaro Cuesta-Dominguez, Ziwei Chen, Thomas Koehnke, Ravindra Majeti, Martin Carroll, Azra Raza, Stavroula Kousteni

Blood (2023) 142 (Supplement 1): 4118.

https://doi.org/10.1182/blood-2023-174485

Published: 2023

Journal Articles

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Blood (2022) 140 (Supplement 1): 1106–1108.

https://doi.org/10.1182/blood-2022-169050

Published: 2022

Journal Articles

Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance

Ioanna Mosialou, Abdullah M Ali, Rachel Adams, Adam Corper, Catherine M Woods, Xiaomin Fan, Azra Raza, Stavroula Kousteni

Blood (2022) 140 (Supplement 1): 2902.

https://doi.org/10.1182/blood-2022-167042

Published: 2022

Journal Articles

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Blood (2021) 138 (Supplement 1): 2598.

https://doi.org/10.1182/blood-2021-148876

Published: 2021

Journal Articles

A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia

Marta Galan-Diez, Florence Borot, Abdullah M. Ali, Junfei Zhao, Eva Gil-Iturbe, Xiaochuan Shan, Xi-Ping Huang, Irwin Kurland, Bryan L. Roth, Matthias Quick, Siddhartha Mukherjee, Raul Rabadan, Martin P. Carroll, Azra Raza, Stavroula Kousteni

Blood (2021) 138 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2021-147741

Published: 2021

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2019) 134 (Supplement_1): 4248.

https://doi.org/10.1182/blood-2019-127435

Published: 2019

Journal Articles

Pharmacological Targeting of Osteoblast-Induced MDS and AML

Ioanna Mosialou, PhD, Marta Galan-Diez, PhD, Andrew Vandenberg, Abdullah Mahmood Ali, PhD, Azra Raza, MD, Stavroula Kousteni, PhD

Blood (2018) 132 (Supplement 1): 5235.

https://doi.org/10.1182/blood-2018-99-119985

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients

Azra Raza, MD, Can Yalçın, Miray Cimist, Ryan Shelton, BS, Syed Fazl Ali Bilgrami, MD, Mark Lawrence Heaney, MD PhD, Abdullah Mahmood Ali, PhD

Blood (2017) 130 (Supplement 1): 5316.

https://doi.org/10.1182/blood.V130.Suppl_1.5316.5316

Published: 2017

Journal Articles

Longitudinal Transcriptome Analysis of Myelodysplatic Syndrome Progression to Acute Myeloid Leukemia: Implications for Prognosis

Etienne De Clara, PhD, Abdullah Mahmood Ali, PhD, Jehanzeb Kayani, Christopher Szeto, PhD, Justin Golovato, Andrew Sedgewick, PhD, Joseph G. Jurcic, MD, Steve Benz, PhD, Shahrooz Rabizadeh, PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 3961.

https://doi.org/10.1182/blood.V130.Suppl_1.3961.3961

Published: 2017

Journal Articles

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Matthew R Janes, PhD, Linda Kessler, BA, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 3957.

https://doi.org/10.1182/blood.V130.Suppl_1.3957.3957

Published: 2017

Journal Articles

Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories

Abdullah Mahmood Ali, PhD, Yumin Huang, Ronald F Pinheiro, MD, Fumin Xue, PhD, Jingping Hu, PhD, Nicholas Iverson, BS, Daniela Hoehn, MDPhD, Diego Coutinho, BS, Joseph Lane, MD, Christopher D. Hillyer, MD, Naomi Galili, PhD, Joseph G. Jurcic, MD, Mohandas Narla, DSc, Xiuli An, MD PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 4244.

https://doi.org/10.1182/blood.V130.Suppl_1.4244.4244

Published: 2017

Journal Articles

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

Ioanna Mosialou, PhD, Alvaro Cuesta-Dominiguez, PhD, Govind Bhagat, MD, Ellin Berman, MD, Azra Raza, MD, Stavroula Kousteni, PhD

Blood (2017) 130 (Supplement 1): 2946.

https://doi.org/10.1182/blood.V130.Suppl_1.2946.2946

Published: 2017

Journal Articles

TET2 Deficiency Led to Expansion of Dysfunctional Erythroid Progenitors

Xiaoli Qu, MS, Lixiang Chen, Yaomei Wang, Yumin Huang, John Hale, Wei Li, Huizhi Zhao, Shijie Zhang, Xinhua Guo, Abdullah Mahmood Ali, PhD, Azra Raza, MD, Mohandas Narla, DSc, Qiaozhen Kang, PhD, Xiuli An, MD PhD

Blood (2017) 130 (Supplement 1): 2202.

https://doi.org/10.1182/blood.V130.Suppl_1.2202.2202

Published: 2017

Journal Articles

Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients

Abdullah Mahmood Ali, PhD, Yumin Huang, Diego Coutinho, BS, Brian Chernak, BA, Etienne De Clara, PhD, Daniela Hoehn, MDPhD, Joseph G. Jurcic, MD, Mohandas Narla, DSc, Xiuli An, MD PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 2952.

https://doi.org/10.1182/blood.V130.Suppl_1.2952.2952

Published: 2017

Journal Articles

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Diego Coutinho, BS, Abdullah Mahmood Ali, PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Karen Bracken, MHS, Joseph G. Jurcic, MD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 1677.

https://doi.org/10.1182/blood.V130.Suppl_1.1677.1677

Published: 2017

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

NARROW

Methylation Biology of a Blood-Based MDS Risk Stratification Test

Serum Amyloid A1 (SAA1) Secreted By the Stromal Microenvironment Drives Malignant Clonal Proliferation in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Pharmacological Targeting of Osteoblast-Induced MDS and AML

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients

Longitudinal Transcriptome Analysis of Myelodysplatic Syndrome Progression to Acute Myeloid Leukemia: Implications for Prognosis

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories

Activation Levels of b-Catenin Signaling in Osteoblasts Define a Threshold for the Development of Myeloid Neoplasia of Variable Severity

TET2 Deficiency Led to Expansion of Dysfunctional Erythroid Progenitors

Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only